It’s a lively place for folks who are into AI companionship, where users can work together, trade real experiences, compare features, and talk about what’s new in AI relationship tools. Lately, with more and more attention on AI companions, the forum has also seen a noticeable rise in activity, so it didn’t really make sense to just stay the same, and the decision was made to expand what the community can offer.

“Our goal at AI Girlfriend Forum has always been to create a welcoming environment for everyone interested in AI companionship,” said of AI Girlfriend Forum. “With our expansion, we’re excited to provide even more resources and opportunities for members to connect, share insights, and stay informed about the rapidly evolving landscape of AI girlfriend technology.”

The expansion is gonna come with new bits, like better conversation threads, topic groupings so it’s easier to browse around, and a bunch of useful resources tied to AI companion platforms.

Members can also expect more connections and more detailed chats about things like chat quality, customization choices, voice interactions, and what’s trending right now across the industry, really.

AI Girlfriend Forum invites everyone—if you’re still a curious newcomer or already a seasoned user to hop in with us on this exciting path, as we keep building a community that leans into fresh ideas, friendly support, and shared know-how in the whole world of AI companionship.

About AI Girlfriend Forum

AI Girlfriend Forum is a kind of online place, where people explore AI companions, virtual girlfriends, and those AI powered relationship chat platforms. It kinda centers on user experiences, feature comparisons, and what’s new lately in AI companionship tech.

So it becomes a discussion hub for folks who are curious about conversational AI, and virtual relationships, kind of together in the same space.

CONTACT: For more information and queries, please contact us on support@aigirlfriend.com

Pinellas Park, FL, July 02, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the Food and Drug Administration. JellyForce is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use, especially if currently taking prescription medications.

JellyForce is a gummy dietary supplement formulated for men, taken as one gummy daily from a 30-count bottle. The formula centers on an 82 mg proprietary blend combining Muira Puama Extract, Maca Extract, Catuaba Extract, Korean Red Ginseng, Ashwagandha, L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract, equivalent to approximately 567 mg of dry powder extracts. JellyForce is produced in the United States in a facility that follows Good Manufacturing Practices (GMP), using ingredients sourced both domestically and internationally.

Gummy-format dietary supplements have become a common way for men to add botanical and amino-acid ingredients to a daily routine without capsules or powders. The category spans adaptogenic herbs such as ashwagandha and maca, circulation-related amino acids such as L-Arginine, and traditional botanicals including muira puama, catuaba, and tribulus terrestris. Ingredients in this category are typically standardized as extracts and combined into a proprietary blend, meaning the total blend weight is disclosed on the supplement facts panel while individual ingredient amounts within the blend are not itemized separately, a common labeling practice across the category.

JellyForce Ingredient Sourcing

Muira Puama Extract is a South American botanical traditionally used in energy- and stamina-focused herbal formulations. Maca Extract is a Peruvian root extract commonly included in men’s wellness formulas for its traditional association with vitality and endurance. Catuaba Extract is a Brazilian botanical traditionally used in energy-focused herbal blends. Korean Red Ginseng is a botanical widely used in traditional Asian herbal practices and often included in vitality-focused supplement formulations. Ashwagandha is an adaptogenic herb studied for its relationship to the body’s stress response and physical energy. L-Arginine is an amino acid the body uses in nitric oxide production, a process linked to blood flow regulation. Tribulus Terrestris is a botanical traditionally used in vitality-focused herbal formulations. Horny Goat Weed Extract is a botanical containing icariin, a compound studied for its role in blood flow-related research.

JellyForce Supplement Facts Panel

The JellyForce supplement facts panel lists a serving size of one gummy, with 30 servings per container. Per serving: 10 calories, 3 g total carbohydrate (1% Daily Value), 3 g total sugars including 3 g added sugar (6% Daily Value), 4 mg sodium (less than 1% Daily Value), and an 82 mg proprietary blend of Muira Puama Extract, Maca Extract, Catuaba Extract, Korean Red Ginseng, Ashwagandha, L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract. Because the blend is proprietary, the panel discloses the combined 82 mg total rather than a separate milligram amount for each of the eight ingredients. Other ingredients listed on the label are Corn Syrup, Cane Sugar, Water, Apple Pectin, Sorbitol Liquid, Natural Flavors, Citric Acid, and Sodium Citrate Dihydrate. JellyForce is produced in a facility that follows Good Manufacturing Practices (GMP).

Ashwagandha Research Context

The National Center for Complementary and Integrative Health, part of the National Institutes of Health, has noted that research shows some ashwagandha preparations may be effective for insomnia and stress, while evidence on its effects on anxiety remains unclear. NCCIH has also noted that some small human studies suggest ashwagandha supplementation may be associated with improvements in strength, VO2 max, and reproductive hormone markers in men, while noting that many available clinical trials have limitations in size and design. Research on muira puama, catuaba, maca, Korean red ginseng, tribulus terrestris, and horny goat weed extract is generally more limited in modern peer-reviewed literature than ashwagandha’s, consisting largely of traditional-use documentation and smaller-scale studies.

Consumer Safety Considerations

The JellyForce label advises that individuals who are pregnant or nursing, taking medications, or managing a medical condition should consult a doctor before using the product, and should discontinue use and consult a doctor if any adverse reaction occurs. JellyForce’s blend includes L-Arginine, an amino acid involved in nitric oxide production and blood flow regulation, and Horny Goat Weed Extract, a botanical containing icariin. Individuals taking blood pressure medication, nitrate medications, or prescription treatments for erectile dysfunction should discuss JellyForce with a healthcare provider before use, given the potential for interaction with medications that affect blood flow or blood pressure. JellyForce should be stored at room temperature between 59 and 86 degrees Fahrenheit, kept tightly closed, and kept out of reach of children. The product should not be used if the seal under the cap is broken or missing.

California Consumer Disclosure (Proposition 65)

California residents should review the JellyForce product label and the official JellyForce website for any warnings required under California’s Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as Proposition 65, before purchase. Any Prop 65 warning obligation rests with the manufacturer and distributor of the product. California consumers with specific questions about Proposition 65 compliance can contact JellyForce directly at contact@Jellyforce.online. Information about Proposition 65 is publicly available through the California Office of Environmental Health Hazard Assessment (OEHHA).

Contact Information

JellyForce customer support is available by email at contact@Jellyforce.online, with support hours from 8 a.m. to 6 p.m. JellyForce is distributed by Info Wealth CO, Pinellas Park, FL 33781, phone 888-338-0317. Product returns are directed to: Attn: Returns, 11870 62nd St N, Largo, FL 33773. Current supplement facts, ingredient sourcing detail, and return and support terms are maintained on the official JellyForce website.

Summary

JellyForce is a gummy dietary supplement for men built around an 82 mg proprietary blend of eight botanical and amino acid ingredients: Muira Puama Extract, Maca Extract, Catuaba Extract, Korean Red Ginseng, Ashwagandha, L-Arginine, Tribulus Terrestris, and Horny Goat Weed Extract. Each 30-gummy bottle is a one-month supply at the labeled dose of one gummy daily. JellyForce is produced in a facility that follows Good Manufacturing Practices (GMP) in the United States.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new dietary supplement, particularly if you are pregnant, nursing, taking medication, or managing a medical condition.

Individual results may vary. Statements regarding vitality, energy, and performance reflect the intended design and traditional use basis of the formula’s ingredients and are not guarantees of individual outcomes.

Product and pricing information referenced in this release reflects information available on the official JellyForce website at the time of publication and is subject to change.

California Consumer Disclosure (Proposition 65): California residents should review the JellyForce product label and the JellyForce official website for any warnings required under California’s Safe Drinking Water and Toxic Enforcement Act of 1986. Any Proposition 65 warning obligation rests with the manufacturer and distributor of the product. Information about Proposition 65 is publicly available through the California Office of Environmental Health Hazard Assessment (OEHHA).

This content includes a link to the official JellyForce website. Compensation may be earned from qualifying purchases made through that link, at no additional cost to the consumer.

CONTACT: contact@Jellyforce.online 888-338-0317

NATO’s eastern flank

By CNBC

[Lyon, France; 02.07.26] TSplus introduces its redesigned TSplus License Portal, a modern solution for software license management for customers, IT professionals and resellers worldwide. Built on user feedback and modern usability standards, the new portal streamlines everyday license administration while laying the foundation for even more powerful management capabilities.

The redesigned interface replaces numerous legacy pages with a unified, intuitive workflow that makes it easier to view, activate and manage TSplus software licenses. Whether managing a single deployment or hundreds of customer environments, users benefit from improved navigation, advanced filtering and a significantly smoother user experience.

A Faster and Smarter Way to Manage TSplus Software Licenses

The new TSplus License Portal is designed to reduce time spent on administrative tasks while improving visibility across software licenses and support subscriptions.

Among the key enhancements already available are:

• A modernized interface that consolidates multiple license management pages into a more streamlined experience.
• Improved filtering and navigation for faster access to license information.
• License version visibility directly within the portal.
• A new Reset Rehost option available to resellers for licenses covered by a valid Updates & Support subscription.
• A simpler process for creating and managing licenses and support coverage.

“Our goal was not simply to redesign the interface, but to reimagine the entire software license management experience,” said the TSplus development team. “Every enhancement has been shaped by user feedback, helping us make everyday administrative tasks faster, clearer and more efficient.”

Continuous Improvements Driven by User Feedback

The redesigned portal marks the first step in the ongoing evolution of the TSplus licensing ecosystem. Additional features currently under development include:

• Bulk actions for managing multiple licenses simultaneously.
• Co-terming capabilities to simplify subscription renewals.
• A tighter integration between licenses and Updates & Support to simplify upgrades and migrations even further.
• Improved visibility of automatic renewal options.

As with every major TSplus development, customer and partner feedback remains central to shaping future improvements. Users are invited to explore the new portal, share their suggestions through the TSplus Insights platform, and follow the progress of submitted ideas in real time on our Feedback and Roadmap page.

The new TSplus License Portal is available now:

• https://license.tsplus.net/new/licenses
• https://license.tsplus.net/new/licenses/add

A Valuable Tool for TSplus Partners

The redesigned License Portal is especially valuable for TSplus resellers and IT service providers managing multiple customer licenses on a daily basis. It complements the many advantages of the TSplus Partner Program, which provides partners with dedicated pricing, sales resources, technical support, marketing tools and early access to new developments.

Organizations seeking to expand their business with TSplus can learn more and apply to become an official TSplus reseller via the Partner page.

—–

About TSplus – Make IT simple.

TSplus is a global software company providing secure, cost-effective solutions for Remote Access, Remote Support, Server Security and application delivery. Serving more than 500,000 businesses in over 140 countries, TSplus empowers organizations of all sizes to securely access their applications and IT infrastructure from anywhere while making it simple. Learn more at https://tsplus.net/.

Survey Results Expected to Drive Refinement of High-Priority Drill Targets Ahead of Maiden Drill Campaign at Vumba

Joe Van Wyk Appointed Vice President, Exploration, to Lead the Company’s Expanding Exploration Programs in Botswana

TORONTO, July 02, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective mining areas in Botswana, today announced that it has commenced a high-resolution airborne geophysical survey across its Vumba Project in Botswana.

The survey is being conducted by Xcalibur Smart Mapping, which began on July 2, 2026 and is expected to take approximately 10 days to complete. The program will cover the Vumba License area and will be followed by a subsequent survey over the Company’s Maitengwe project to the north. The program marks a pivotal step in advancing One Bullion’s exploration strategy toward the definition and prioritization of drill targets.

“This is a significant step forward for One Bullion as we continue to systematically advance Vumba toward drilling and reflects the disciplined, data-driven approach that underpins everything we do,” said Adam Berk, Chief Executive Officer of One Bullion. “This survey moves us decisively into the next phase of our exploration program. Integrating the geophysical data with our recent high-grade artisanal workings results will allow us to refine our drill targets with confidence as we advance toward a maiden drill campaign at Vumba. With strong momentum across the project, we look forward to providing further updates as results become available.”

Highlights

• High-resolution airborne geophysical survey commenced over the Vumba License, conducted by Xcalibur Smart Mapping, beginning July 2, 2026
• Survey expected to take approximately 10 days to fly the Vumba License, followed by a survey of the Maitengwe project to the north
• Initial survey results and interpretation anticipated by late July 2026
• Geophysical data to be integrated with the Company’s geology, drill database, sampling, and recent high-grade assay results to refine and prioritize drill targets
• Appointed Joe Van Wyk as Vice President, Exploration, a geologist with more than 20 years of international mining experience, to provide on-the-ground oversight of the Company’s field operations in Botswana
• Maiden drill campaign at Vumba is fully funded and planned to follow the survey, targeting ~3,000 meters expected to commence August 2026

Geophysical Survey at Vumba
As previously announced, One Bullion engaged Xcalibur Smart Mapping to conduct a high-resolution airborne, horizontal-gradient magnetic survey across the Vumba License area, to be followed by the same survey configuration of the Maitengwe project. The survey is expected to deliver detailed structural and lithological insights that will significantly enhance target definition at depth and along strike within the broader greenstone belt. The integration of geophysical data with the Company’s drill database, geological mapping, sampling, and assay results, including the recently reported high-grade gold results at Vumba, is expected to accelerate the refinement and prioritization of high-confidence drill targets across the emerging Vumba mineralized corridor.

Strengthening the In-Country Exploration Team
To support its expanding exploration program initiatives in Botswana, One Bullion has appointed Joe Van Wyk as Vice President, Exploration. Mr. Van Wyk is a geologist with more than 20 years of international experience spanning exploration, feasibility, and project development. He began his career as an exploration and resource geologist with AngloGold Ashanti and Gold Fields, leading regional target generation and quality-assurance/quality-control programs across Africa, the Americas, and Australia. He subsequently led feasibility and resource modelling as a Senior Resource Geologist with TWP Projects / WorleyParsons. More recently, he has held senior executive and advisory roles across the African mining sector, including as Founder and Chief Executive Officer of KiBOKO Consulting. Mr. Van Wyk holds a BSc and a BSc (Honours) in Geology from the University of Pretoria, South Africa. Based in Botswana, Mr. Van Wyk will lead overseeing the on-site exploration activities, the field camp, and the Company’s geological team, providing full operational oversight as drilling preparations advance. His appointment strengthens the Company’s technical leadership as it advances Vumba toward its maiden drill program and continues to unlock the broader potential of its Botswana assets.

Next Steps
Upon completion of the Vumba survey, the Company expects to receive and interpret the geophysical data over an approximately 10-day period, with the goal of integrating these results into refined drill targeting. One Bullion is concurrently advancing toward its maiden drill campaign at Vumba, and is currently negotiating a drilling contract and finalizing contract terms. Subject to survey results and contract execution, the Company is targeting a drill program of approximately 3,000 meters across approximately 15 holes (each ranging from surface to approximately 200 meters depth), expected to commence in August 2026. The Company will provide further updates as the survey progresses and as drilling plans are confirmed.

Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Rory Kutluoglu, P.Geo., a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects, who is independent of One Bullion.

About One Bullion
One Bullion Ltd. (TSXV: OBUL) is a Toronto-based gold exploration company focused on advancing high-quality gold assets in Botswana, one of Africa’s most stable and mining-friendly jurisdictions. Established in 2018, the company controls approximately 8,004 km² of prospective land across three greenstone belt-hosted gold projects, including Vumba, Kraaipan, and Maitengwe. One Bullion’s strategy centers on disciplined, data-driven exploration combining modern geological methods with advanced targeting to identify and test high-priority gold targets while maintaining a commitment to environmental stewardship, community engagement, and long-term value creation for stakeholders.

Forward-Looking Information
This news release includes forward-looking information within the meaning of Canadian and U.S. securities laws. Statements containing the words “believe”, “expect”, “intend”, “should”, “seek”, “anticipate”, “will”, “positioned”, “project”, “risk”, “plan”, “may”, “estimate”, or, in each case, their negative and words of similar meaning, are intended to identify forward-looking information. Forward-looking information, including but not limited to, the nature and timing of future exploration activities of the Company (including the geophysical survey and any planned drill program), the success of the Company’s existing and future business strategies and implementation (including with respect to potential future acquisitions, timelines for permitting and exiting of projects and potential return on capital), any resulting growth in the Company’s operations or financial performance as a result of such strategies and implementation, trends in the Company’s business or the mineral exploration industry, the prospective nature of the Company’s properties, the uncertainty of mineral resource estimations and the availability of funding are each subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information, including risks related to the regulatory and legal framework of the mineral resource industry; general business, economic and competitive uncertainties; market risks; risks with respect to permitting; risks that the Company not be able to develop its properties as currently proposed or at all, foreign currency risk and risks associated with the Company’s operations in Botswana. There may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Certain statements included in this news release may be considered “financial outlook” for the purposes of applicable securities laws, and such financial outlook may not be appropriate for purposes other than evaluating the information in this news release. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this news release, those results or developments may not be indicative of results or developments in subsequent periods. There can be no assurance that the performance of the Company will be comparable to that achieved previously. Moreover, past performance is not indicative of future results. Forward-looking information contained in this news release is based on the beliefs and expectations of the Company’s management, which the Company believes are reasonable as of the current date, and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of OBUL and actual future results may differ materially from current expectations. You should not place undue reliance on forward-looking information. Except as required by applicable law, the Company assumes no obligation to update or revise any forward-looking information in this news release to reflect new events or circumstances.

Cautionary Note Regarding United States Securities Laws
This News Release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of OBUL or any entity related thereto, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of OBUL have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons,” as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

Contact Information:
Adam Berk, Chief Executive Officer
OneBullion@KCSA.com

Investor Contact:
KCSA Strategic Communications
Jack Perkins or Valter Pinto
T: 212-896-1254
OneBullion@KCSA.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Safety over privacy

By CNBC

The Volkswagen Law

‘A strategic step’

Shares of Volkswagen so far this year.

By CNBC

The big story

The frenzied adoption

Need to know

By CNBC

Silver Spring, MD, July 01, 2026 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT). This is the first gene therapy approved for patients aged 2 years and older with SCD.

Casgevy has been previously approved for the treatment of patients aged 12 years and older with SCD with recurrent VOCs or TDT.

“With today’s decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER). “The FDA is committed to prioritizing and speeding up the review of products that address critical U.S health priorities through expedited review programs, including the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program. These initiatives are designed to advance therapies for diseases with significant unmet medical needs, enabling faster access to innovative treatments while upholding the FDA’s rigorous gold-standard requirements for safety and effectiveness.”

SCD affects red blood cells (RBCs), which contain hemoglobin, a protein that transports oxygen throughout the body. SCD can cause various symptoms and health issues, including episodes of severe pain called sickle cell crises or VOCs.

Thalassemia is a genetic blood disorder that causes the body to have an abnormally low level of hemoglobin, resulting in reduced oxygen delivery to the body’s tissues. In some cases, individuals require regular blood transfusions to maintain adequate levels of functional hemoglobin.

Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion. The cells are edited using CRISPR/Cas9, a type of genome editing technology, and then engrafted in the body’s bone marrow. CRISPR/Cas9 can be directed to a specific spot in DNA, where it cuts the genetic material so that DNA can be accurately removed, added, or replaced. In patients with severe SCD, this treatment increases a type of hemoglobin which is called fetal hemoglobin (HbF). This helps prevent RBCs from forming into abnormal sickle shapes and addresses the underlying cause of disease, thereby eliminating VOCs.

In patients with TDT, treatment increases HbF levels and total hemoglobin levels, hence eliminating dependence on regular RBC transfusions.

Full myeloablative conditioning, a high-intensity preparatory treatment given to patients before they receive a stem cell transplant or gene therapy, is administered prior to treatment with Casgevy.

“These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” said Megha Kaushal M.D., MSc, Acting Deputy Director of the Office of Therapeutic Products in CBER and pediatric hematologist. “Grounded in the scientific evidence that earlier treatment reduces the risk of lasting end-organ damage, making this therapy available to younger patients opens a critical window for intervention and gives these children a meaningful chance at a healthier future.”

The safety and effectiveness of Casgevy in patients aged 5 years to less than 12 years with SCD were evaluated in a clinical trial which included 11 patients. All eight patients who were evaluable for efficacy achieved the primary efficacy outcome of VF12 (no protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after infusion with Casgevy).

The efficacy and safety of Casgevy in patients 5 years to less than 12 years of age with TDT were evaluated in a trial of 15 patients. Eight of the nine efficacy evaluable patients with TDT achieved transfusion independence for 12 consecutive months, with a median duration of transfusion independence of 20.1 months.

Based on product characteristics and clinical study data, extrapolation to the younger pediatric age population was granted to expand the indication to 2 years of age and above for both conditions.

The most common adverse reactions were mucositis (inflammation of mucous membranes) and febrile neutropenia (fever associated with low levels of a type of white blood cell called neutrophils) in patients with SCD and in patients with TDT, and decreased appetite in patients with SCD. Additionally, the prescribing information contains warnings for neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and off-target genome editing risk (refers to the possibility that the CRISPR/Cas9 editing process may make unintended edits to parts of the genome other than the intended target site).

The approval decision was granted just 53 days after filing and represented the eighth approval selected for the Commissioner’s National Priority Voucher (CNPV) pilot program. The FDA granted Casgevy Orphan Drug, regenerative medicine advanced therapy (RMAT), and Fast Track designations.

The FDA granted the approval to Vertex Pharmaceuticals, Incorporated.

Contact Info

U.S. Food and Drug Administration
FDAPressAlerts@fda.hhs.gov
+1 202-690-6343

CHICAGO, July 01, 2026 (GLOBE NEWSWIRE) — PetPivot, a smart cat litter box technology brand focused on cleaner and more efficient pet care, has donated 10 Autoscooper 12 fully automatic smart litter boxes to PAWS Chicago as part of the company’s broader charitable support program for animal shelters and rescue organizations. The donated units are being distributed to PAWS Chicago foster families, where they are intended to help improve litter hygiene for foster cats living in temporary home-care environments. The donation supports cats that may be recovering, adjusting to new surroundings, or awaiting adoption while receiving care outside of a shelter setting.

The contribution reflects PetPivot’s growing effort to provide practical pet care technology to rescue groups, shelters, and foster-based animal welfare programs. Rather than focusing only on private households, the company’s charitable initiative is designed to help organizations and caregivers address everyday care needs, including cleanliness, routine litter maintenance, and comfort for cats in transitional care.

“For foster families, litter care can be a daily challenge, particularly when caring for cats that require consistency, close monitoring or a calmer recovery environment,” said Raymond, Public Relations Manager for PetPivot. “However, this Autoscooper 12 is designed to automate routine litter box cleaning, helping maintain a cleaner space while reducing repetitive manual maintenance for caregivers.”

PetPivot’s rescue support initiative comes as the company continues to expand its presence in the smart pet care market. The company has sold more than 300,000 units globally and has expanded into major retail and e-commerce channels, including Amazon, TikTok Shop, Walmart, and Chewy. Through its charitable giving program, PetPivot aims to connect that growth with direct support for animal welfare organizations and the foster families who help pets move toward adoption.

This donation to PAWS Chicago marks one step in PetPivot’s developing effort to support shelters, rescues, and foster networks with technology that can make day-to-day cat care cleaner, easier, and more manageable. PetPivot plans to continue identifying opportunities to support animal welfare organizations through product donations and practical care-focused initiatives.

About PetPivot
PetPivot is a cat litter box technology brand focused on smart pet care products designed to make everyday pet ownership easier, cleaner, and more efficient. Its flagship product, the Autoscooper 12, is a fully automatic smart litter box built with hardware-level safety features, including seven internal infrared sensors, a front touch sensor, and a semi-gear open cabin structure designed to help ensure cats have a safe physical exit at all times. Users can learn more at www.petpivot.com.

About PAWS Chicago
PAWS Chicago is a no-kill animal welfare organization located in Chicago. Founded in 1997, the organization has worked to end the unnecessary euthanasia of homeless cats and dogs in Chicago. The organization supports more than 27,000 homeless and at-risk pets each year through medical and adoption programs, and provides treatment and rehabilitation for approximately 5,000 sick or injured animals. Since its founding, PAWS Chicago has helped reduce the number of homeless pets euthanized in Chicago by 88.8%. To support PAWS Chicago’s mission, users can visit pawschicago.org.

Contact

Public Relations Manager
Raymond
PetPivot
media@petpivot.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/171d49db-fca6-475f-8c7d-04a7239b43d7